title: [Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
abstract: Strong inhibition of acid secretion could be able to decrease gastric and duodenal ulcer early rebleeding. OBJECTIVE--The aim of this double blind randomized trial was to compare early rebleeding rates of 2 groups of patients treated with ranitidine (600 mg/day) or lansoprazole (60 mg/day) per os for 6 consecutive days. METHODS--Seventy five patients with a high risk of rebleeding (clinical and endoscopical criteria) were included in this trial. These ulcers were Ia (n = 10), Ib (n = 20), IIa (n = 13), IIb (n = 32) in Forrest classification. RESULTS--Nineteen out of 75 patients rebled (25.3%): 11 out of 37 (30%) and 8 out of 38 (21%) in the ranitidine and lansoprazole groups respectively. Rates of rebleeding were 10%, 12.5%, 36% and 29% respectively in the ulcers grade Ia (previously treated with endoscopic sclerosis), Ib, IIa and IIb in the Forest classification. CONCLUSION--The rates of rebleeding were not statistically different in the 2 groups of treatment. The high rebleeding rates observed with Forrest IIa and IIb and duodenal ulcers support the need of haemostatic endoscopic therapy associated to antisecretory treatment in such patients.
authors.affiliation: Service des Maladies de l'Appareil Digestif et de la Nutrition, Hôpital Charles-Nicolle, CHU, Rouen.
authors.forename: P
authors.initials: P
authors.lastname: Michel
authors.forename: C
authors.initials: C
authors.lastname: Duhamel
authors.forename: B
authors.initials: B
authors.lastname: Bazin
authors.forename: J L
authors.initials: JL
authors.lastname: Raoul
authors.forename: B
authors.initials: B
authors.lastname: Person
authors.forename: M A
authors.initials: MA
authors.lastname: Bigard
authors.forename: J L
authors.initials: JL
authors.lastname: Legoux
authors.forename: V
authors.initials: V
authors.lastname: Sallerin
authors.forename: R
authors.initials: R
authors.lastname: Colin
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000150:complications*; D016099:Endoscopy, Gastrointestinal; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control* / Q000601:surgery; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use*; D012008:Recurrence; D013276:Stomach Ulcer / Q000150:complications*; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D011899:Ranitidine; D009853:Omeprazole
vernacular_title: Lansoprazole versus ranitidine dans la prévention des récidives précoces des hémorragies digestives ulcéreuses gastro-duodénales. Etude multicentrique randomisée en double aveugle.